Foresite Capital Management VI LLC Takes $19.75 Million Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Foresite Capital Management VI LLC purchased a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 12,500,000 shares of the company's stock, valued at approximately $19,750,000. RAPT Therapeutics makes up 8.8% of Foresite Capital Management VI LLC's investment portfolio, making the stock its 4th biggest position. Foresite Capital Management VI LLC owned approximately 35.76% of RAPT Therapeutics at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Picton Mahoney Asset Management raised its stake in shares of RAPT Therapeutics by 994.4% during the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock worth $26,000 after buying an additional 14,697 shares during the period. JPMorgan Chase & Co. raised its position in RAPT Therapeutics by 298.2% during the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock worth $34,000 after acquiring an additional 25,130 shares during the period. Sei Investments Co. purchased a new position in RAPT Therapeutics during the fourth quarter valued at $64,000. Barclays PLC grew its position in shares of RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company's stock valued at $79,000 after purchasing an additional 29,195 shares during the period. Finally, SG Americas Securities LLC increased its stake in shares of RAPT Therapeutics by 401.9% during the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company's stock worth $84,000 after purchasing an additional 42,636 shares in the last quarter. 99.09% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of RAPT Therapeutics in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, RAPT Therapeutics currently has a consensus rating of "Hold" and an average price target of $4.00.

RAPT Therapeutics Price Performance

NASDAQ RAPT traded up $0.05 during trading hours on Friday, hitting $0.97. 904,905 shares of the company's stock traded hands, compared to its average volume of 1,279,842. The firm's 50-day moving average is $1.06 and its 200-day moving average is $1.29. RAPT Therapeutics, Inc. has a 52-week low of $0.75 and a 52-week high of $8.58. The company has a market capitalization of $127.62 million, a PE ratio of -0.35 and a beta of -0.29.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.69). Equities research analysts predict that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.